Egfr inhibitor for treating cancers comprising atypical egfr mutations
AssigneeOric Pharmaceuticals, Inc.
InventorsMelissa R. JUNTTILA, Anneleen DAEMEN, Pratik Sharad MULTANI, Edna Chow MANEVAL, Rupal PATEL
Life of this patent
Estimating the term…
Abstract
The present application provides methods of treating cancer in an individual in need thereof, wherein in the cancer in the individual has been determined to comprise one or more atypical epidermal growth factor receptor (EGFR) mutations, comprising administering to the individual (R)—N-(2-(4-(4-cyclopropylpiperazin-1-yl)piperidin-1-yl)-5-((6-(3-(3,5-difluorophenyl)isoxazolidin-2-yl)pyrimidin-4-yl)amino)-4-methoxyphenyl)acrylamide, or a pharmaceutically acceptable salt thereof.
Claims15
A method of treating cancer in an individual in need thereof, wherein in the cancer in the individual has been determined to comprise one or more atypical epidermal growth factor receptor (EGFR) mutations, comprising administering to the individual (R)—N-(2-(4-(4-cyclopropylpiperazin-1-yl)piperidin-1-yl)-5-((6-(3-(3,5-difluorophenyl)isoxazolidin-2-yl)pyrimidin-4-yl)amino)-4-methoxyphenyl)acrylamide, or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.